Extension to in-use stability time
FARNBOROUGH, England,  March, 2020: Flexipharm Austrading, the UK specialty pharmaceutical
company focused on supplying the NHS with Better, Critical Care Medicines, today announced an
important improvement to the ‘Summary of Product Characteristics’ for its differentiated arsenic
trioxide injection product, Arsenic Trioxide Phebra (1mg/ml concentrate for solution for infusion).